Pancatalytic Biomaterials Enable Inflammation-Related Disease Intervention

Abstract

Inflammatory disease (ID) is an umbrella term encompassing all conditions where chronic inflammation serves as the central pathogenic mechanism, impose a profound global health burden due to their high morbidity, mortality, and socioeconomic impact. These pathologies are unified by dysregulated inflammatory cascades, oxidative stress, and immune microenvironment imbalances, which drive progressive tissue damage and organ dysfunction. Conventional therapies, including immunosuppressants and anti-inflammatory agents, often provide only palliative relief, fail to address root causes, and carry risks of systemic toxicity. The emerging pancatalytic biomaterials, which involves the holistic management of preparation (P) of catalyst, activation (A) of biological effect and nontoxic treatment (N) of diseases, offer a transformative paradigm for precision management of ID. These pancatalytic biomaterials constitute the operational foundation of pancatalytic therapy, a multidisciplinary framework that integrates catalytic biomaterials with catalytic biology and catalytic medicine to systematically orchestrate pathological processes via P-A-N framework, ultimately redefining therapeutic strategies from toxic theapy to nontoxic treatment. This review systematically investigates the rational design of pancatalytic biomaterials, classifying them into inorganic, organic, and organic/inorganic hybrid systems based on the composition. The therapeutic applications of pancatalytic biomaterials across cardiovascular, neurological, respiratory, sensory and other systems are comprehensively summarized. Finally, the current facing challenges are discussed, and future developments and trends in employing pancatalytic biomaterials for inflammatory disease treatment are projected, thereby advancing further research and clinical translation.